Cargando…
Concomitant granule cell neuronopathy in patients with natalizumab-associated PML
Granule cell neuronopathy (GCN) is a rare JC virus infection of the cerebellar granule cell neurons in immunocompromised patients. On brain imaging, GCN is characterized by cerebellar atrophy which can be accompanied by infratentorial white matter lesions. The objective of this study is to investiga...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826658/ https://www.ncbi.nlm.nih.gov/pubmed/26810721 http://dx.doi.org/10.1007/s00415-015-8001-3 |
_version_ | 1782426359022223360 |
---|---|
author | Wijburg, Martijn T. Siepman, Dorine van Eijk, Jeroen J. J. Killestein, Joep Wattjes, Mike P. |
author_facet | Wijburg, Martijn T. Siepman, Dorine van Eijk, Jeroen J. J. Killestein, Joep Wattjes, Mike P. |
author_sort | Wijburg, Martijn T. |
collection | PubMed |
description | Granule cell neuronopathy (GCN) is a rare JC virus infection of the cerebellar granule cell neurons in immunocompromised patients. On brain imaging, GCN is characterized by cerebellar atrophy which can be accompanied by infratentorial white matter lesions. The objective of this study is to investigate the prevalence of MRI findings suggestive of GCN in a large natalizumab-associated progressive multifocal leukoencephalopathy (PML) cohort. MRI scans from before, at the time of, and during follow-up after diagnosis of PML in 44 natalizumab-treated MS patients, and a control group of 25 natalizumab-treated non-PML MS patients were retrospectively reviewed for imaging findings suggestive of GCN. To assess and quantify the degree of cerebellar atrophy, we used a 4 grade rating scale. Three patients in the PML group showed imaging findings suggestive of GCN and none in the control group. In two of these PML patients, cerebellar atrophy progressed from grade 0 at the time of diagnosis of isolated supratentorial PML to grade 1 and 2 after 2.5 and 3 months, respectively, in the absence of infratentorial white mater lesions. The third patient had grade 1 cerebellar atrophy before diagnosis of infra- and supratentorial PML, and showed progression of cerebellar atrophy to grade 2 in the 3 months following PML diagnosis. None of the other eight patients with infratentorial PML lesions developed cerebellar atrophy suggestive of GCN. Three cases with imaging findings suggestive of GCN were detected among 44 natalizumab-associated PML patients. GCN may, therefore, be more common than previously considered in natalizumab-associated PML patients. |
format | Online Article Text |
id | pubmed-4826658 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-48266582016-04-20 Concomitant granule cell neuronopathy in patients with natalizumab-associated PML Wijburg, Martijn T. Siepman, Dorine van Eijk, Jeroen J. J. Killestein, Joep Wattjes, Mike P. J Neurol Original Communication Granule cell neuronopathy (GCN) is a rare JC virus infection of the cerebellar granule cell neurons in immunocompromised patients. On brain imaging, GCN is characterized by cerebellar atrophy which can be accompanied by infratentorial white matter lesions. The objective of this study is to investigate the prevalence of MRI findings suggestive of GCN in a large natalizumab-associated progressive multifocal leukoencephalopathy (PML) cohort. MRI scans from before, at the time of, and during follow-up after diagnosis of PML in 44 natalizumab-treated MS patients, and a control group of 25 natalizumab-treated non-PML MS patients were retrospectively reviewed for imaging findings suggestive of GCN. To assess and quantify the degree of cerebellar atrophy, we used a 4 grade rating scale. Three patients in the PML group showed imaging findings suggestive of GCN and none in the control group. In two of these PML patients, cerebellar atrophy progressed from grade 0 at the time of diagnosis of isolated supratentorial PML to grade 1 and 2 after 2.5 and 3 months, respectively, in the absence of infratentorial white mater lesions. The third patient had grade 1 cerebellar atrophy before diagnosis of infra- and supratentorial PML, and showed progression of cerebellar atrophy to grade 2 in the 3 months following PML diagnosis. None of the other eight patients with infratentorial PML lesions developed cerebellar atrophy suggestive of GCN. Three cases with imaging findings suggestive of GCN were detected among 44 natalizumab-associated PML patients. GCN may, therefore, be more common than previously considered in natalizumab-associated PML patients. Springer Berlin Heidelberg 2016-01-25 2016 /pmc/articles/PMC4826658/ /pubmed/26810721 http://dx.doi.org/10.1007/s00415-015-8001-3 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Communication Wijburg, Martijn T. Siepman, Dorine van Eijk, Jeroen J. J. Killestein, Joep Wattjes, Mike P. Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
title | Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
title_full | Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
title_fullStr | Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
title_full_unstemmed | Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
title_short | Concomitant granule cell neuronopathy in patients with natalizumab-associated PML |
title_sort | concomitant granule cell neuronopathy in patients with natalizumab-associated pml |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826658/ https://www.ncbi.nlm.nih.gov/pubmed/26810721 http://dx.doi.org/10.1007/s00415-015-8001-3 |
work_keys_str_mv | AT wijburgmartijnt concomitantgranulecellneuronopathyinpatientswithnatalizumabassociatedpml AT siepmandorine concomitantgranulecellneuronopathyinpatientswithnatalizumabassociatedpml AT vaneijkjeroenjj concomitantgranulecellneuronopathyinpatientswithnatalizumabassociatedpml AT killesteinjoep concomitantgranulecellneuronopathyinpatientswithnatalizumabassociatedpml AT wattjesmikep concomitantgranulecellneuronopathyinpatientswithnatalizumabassociatedpml |